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Abstract 
ANCA associated vasculitis  is a serious, very often recurrent disease that despite the 
current standard treatment with high-dose glucocorticoids and either cyclophosphamide or 
rituximab, patients have a nine-fold increased mortality risk in the first year compared with 
healthy controls, attributed to infections, vasculitis activity, and renal disease.  
During the last few years, novel findings have suggested that activation of the complement 
system, in particular the alternative complement system, has a significant role in ANCA 
associated vasculitis pathogenesis. Detection of several components of this system in the 
circulation and urine reflects disease activity, and thus may be useful for clinical prognosis 
and to set up personalised treatments. In fact, some components of the complement 
system, such as C5a, might be potential targets for therapy. 
In this Review an update on clinical evidence for the role of complement activation in AAV 
is provided and subsequently we discuss potential therapeutic strategies that target 
complement components and open the way for clinical use of this target therapy in the 
near future. 
Introduction 
The spectrum of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) 
includes three clinical phenotypes: granulomatosis with polyangiitis (GPA, Wegener’s 
granulomatosis), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with 
polyangiitis (EGPA, Churg-Strauss syndrome). The availability of ANCA as a biomarker 
eases diagnostics and provides prognostic information. A cytoplasmic pattern (c-ANCA) 
and the target autoantigen proteinase 3 (PR3) are predominantly present in GPA (40-50% 
in localised GPA, 70-95% in generalised cases), while the perinuclear pattern (p-ANCA) 
and presence of myeloperoxidase (MPO) are observed in most MPA cases (70-95%) and 
to a lesser extent in EGPA (around 40%) (1,2). GWAS identified MHC and non-MHC 
associations with AAV and genetic associations better correlated with the ANCA serotype 
than with the clinical phenotype, supporting the concept that PR3 ANCA-and MPO ANCA-
associated vasculitis are distinct autoimmune syndromes and should replace classification 
based on the clinical phenotype (3). 
AAV is a serious, very often recurrent disease that despite the current standard treatment 
with high-dose glucocorticoids and either cyclophosphamide or rituximab, patients have a 
nine-fold increased mortality risk in the first year compared with healthy controls, attributed 
to infections, vasculitis activity, and renal disease (4). The prevalence of kidney 
involvement in AAV is 75–90%, and also impacts patients’ quality of life and morbidity, 
particularly among those with end stage renal disease (ESRD) (4). Moreover, a histological 
subgrouping of diagnostic renal biopsies has been proposed to aid in prognosis (5). Renal 
biopsy and baseline estimated glomerular filtration rate (eGFR) remain the most important 
outcome predictors available for ANCA associated renal vasculitis. The severity of 
proteinuria after the diagnosis is also a marker of the degree of injury and MPO-ANCA 
positive patients have a worse renal prognosis due to more severe chronic damage at the 
time of diagnosis (6). 
Currently used therapies contribute to more than half of the increased risk of mortality and 
represent an important cause of comorbidities. Among them, glucocorticoids are 
associated with an increased infection risk and increase the risk to develop cardiovascular 
complications, particularly hypertension and diabetes mellitus (7-12). 
The histopathological hallmark in the renal biopsy of patients with AAV is pauci-immune 
necrotising crescentic glomerulonephritis, which is characterised by no immunoglobulin 
and complement deposition in the glomeruli. In addition, hypocomplementemia is 
infrequent in patients with AAV.(4) These characteristics diverted the attention on a 
potential role of the complement system in the development of AAV over decades. 
However, gathering evidence during the last few years has suggested that activation of the 
complement system, in particular the alternative complement system, has a significant role 
in AAV pathogenesis. Detection of several components of this system in the circulation and 
urine reflect disease activity, and thus may be useful for clinical prognosis and to set up 
personalised treatments. In fact, some components of the complement system, such as 
C5a, might be potential targets for therapy. 
In this Review an update on clinical evidence for the role of complement activation in AAV 
is provided and subsequently we discuss potential therapeutic strategies that target 
complement components and could improve patient and renal outcomes in this clinical 
context. 
Complement and Glomerular disease 
The complement system and its regulatory proteins are components of the innate immune 
system with multiple roles in glomerulonephritis (GN) (13-17). The innate immune 
response involves immediate complement activation through the mannose binding lectin 
(MBL) or alternative pathways (13-16). Activation of the MBL pathway proceeds when MBL 
binds to mannose residues on pathogens and activates the serine proteases, MASP-1 and 
MASP-2, leading to activation of C4 and C2. The alternative pathway is activated 
spontaneously by hydrolysis of C3 and amplified by defects in complement regulation. 
Non-Ig zymogens such as damaged cells and bacterial and viral proteins can also activate 
the alternative pathway beginning directly at C3. The same initiating event may activate 
more than one pathway (17). 
Complement activation products are the main mediators of antibody-induced GN. Usually 
this involves C1q binding to Immunoglobulins that leads to classic pathway activation 
through C4 and C2; however, some immunoglobulins, depending on their level of 
glycosylation, can also bind MBL. IgG subclasses 1 and 3 and IgM are classic complement 
pathway activators, whereas IgG 2 and 4, IgA, IgD, and IgE activate complement poorly 
(16-17). 
All complement activation pathways proceed through cleavage of C3 and C5 leading to 
release of chemotactic factors such as C5a that attract inflammatory cells (neutrophils, 
macrophages, and platelets) when abutting the circulation as well as formation of the 
terminal membrane attack complex (C5b-9) (13-15). 
Sublytic quantities of C5b-9 can insert into lipid bilayers of adjacent glomerular cell 
membranes, initiate several signaling pathways, and convert these cells to effector cells 
which may proliferate; release a variety of cytokines, growth factors, eicosanoids, oxidants, 
proteases, and other acute inflammatory mediators; as well as up-regulate production of 
matrix components that contribute to chronic scarring and sclerosis.(18-20) Complement 
activation products like C5a can also activate toll-like receptors (TLRs).(20) Complement 
activation in vivo is tightly regulated by a number of circulating and cell-bound complement 
regulatory proteins, whose functions, mutations and deficiencies are also important in the 
development of several glomerular diseases. Abnormalities in serum complement profiles 
are in some cases helpful in assessing the nature of the underlying disease and its activity, 
but significant complement-mediated injury may occur locally without alterations in 
circulating complement components.(13-14) 
Complement activation in the AAV pathogenesis  
Until recently, the complement system was not studied in AAV because of its pauci-
immune nature with absence of complement deposition in affected tissues and its rare 
association with hypocomplementemia. (21-22) The first evidence for a role of complement 
in AAV pathogenesis came from observations in animal studies. These models 
demonstrated that the alternative complement pathway was essential to the development 
of a necrotising crescentic GN.(23) Complement-depleted mice pretreated with cobra 
venom factor were protected from the development of GN, as evidenced after the 
induction of a pauci-immune crescentic GN by the administration of anti-MPO splenocytes 
to the mice. In these models, complement depletion prevented inflammation and crescent 
formation. Moreover, other studies clearly defined the contribution of the complement 
system to AAV pathogenesis. C5-knockout mice aiming to block activation of the terminal 
complement pathway were also protected as were mice lacking complement factor B, a 
critical regulatory component of the alternative complement pathway. By the contrary, C4-
knockout mice developed the disease. In brief, these data confirm that the alternative 
pathway and the activation of complement C5 and the terminal complement pathway are 
critical to AAV pathogenesis.  
Furthermore, supernatant from human neutrophils stimulated with either anti-MPO or PR3 
IgG activated complement in normal human serum, prompting to the release of a 
complement-activating product by the ANCA-stimulated neutrophils. (23) 
Additionally, pretreatment with a monoclonal antibody blocking C5 avoided the 
development of GN in mice and the lesion may be halted when given to mice after GN had 
been established. (24) 
Animal data were interpreted with caution given the important differences between mice 
model and men, and consequently generated the reassessment of human data. In 
agreement with the results generated by animal models, this reevaluation confirmed that 
there were some clues that complement activation plays a role in human AAV. (25) Despite 
that the intensity of the staining is not as bright as other observed in diverse GNs, renal 
biopsies of AAV patients do stain positive for some complement activation proteins.(22) 
Lately, investigation of renal biopsies of patients with ANCA-associated GN found an 
association between those biopsies showing presence of immune deposits and proteinuria 
(26), as well as between alternative pathway proteins and crescent formation (22,27). 
Other signs of complement activation in human AAV include increased levels of urinary 
alternative pathway activation products and presence of alternative pathway activation 
fragments in the serum.(28-29) Moreover, a study confirmed the presence of 
hypocomplementaemia in a small group of patients with worst overall and renal prognosis.
(30) 
Finally, a proteomic analysis of renal tissues from AAV patients with ANCA-negative GN 
showed larger amounts of C3 and C9 deposition compared with ANCA-positive patients 
suggesting that ANCA-negative AAV was as a separate disease phenotype, promoted by a 
specific alteration in the activation of the alternative complement pathway. (31) 
Since some years, the role of neutrophils in complement activation (both classical and 
alternative pathways) by expelling neutrophil extracellular traps (NETs) was well 
characterised.(32-33). In AAV, a study reported that neutrophils activated by MPO-ANCA 
released factors that had the capacity to activate the alternative complement pathway with 
the involvement of microparticles (34) or NETs (32-35). 
From another point of view, a study showed that complement factor H, the main negative 
regulator of the alternative complement pathway, inhibits neutrophil activation by ANCA. 
Nonetheless, factor H from patients with active AAV was deficient in its ability to bind 
neutrophils and inhibit their activation suggesting that the complement system regulators 
may also play a protective role in neutrophil activation in AAV. (36) 
Even more, complement activation in AAV may not only result in neutrophil degranulation, 
but may also impact on the coagulation cascade. The effect of C5a on both neutrophils 
and endothelial cells to upregulate tissue factor and initiate the extrinsic pathway of 
coagulation is well known (37). Platelets express C5a receptors and activated platelets 
may in turn push on complement and promote a vicious circle of neutrophils degranulation, 
coagulation, and lingering complement activation. (38) 
Alternative complement pathway profile for disease stratification  
In 2015, Manenti et al. reported, in a study that included 46 patients with AAV, that 35% of 
these individuals had decreased levels of C3 in serum, and this finding was associated 
with decreased renal survival and the presence of renal thrombotic microangiopathy in the 
biopsy (39). Recently, a study in 76 AVV patients reported that only 5% had 
hypocomplementaemia, however, this finding implied worst prognosis with lower overall 
and renal survival in this subset of individuals (30). 
Moreover, the plasma level of properdin in patients with AAV in active stage was 
significantly lower than that in normal controls. The level of properdin inversely correlated 
with the proportion of crescents in renal specimens of AAV. (29) 
Urine Levels of Bb, C3a, C5a and C5b−9 were higher in patients with active AAV than in 
patients in remission and levels of Bb correlated directly with serum creatinine, and 
inversely with the proportion of normal glomeruli in renal biopsies.(40) 
Complement deposits in renal tissue may also be a marker of disease severity. Their 
presence has been correlated with worst renal function and proteinuria at presentation; 
and a higher proportion of glomerular crescents and severe tubulointerstitial injury 
(22,27,41). In fact, C3c deposition was found in renal biopsies and was associated with 
poorer renal function. C5b−9, C3d, and factor B, but not C4d, could be detected in active 
glomerular lesions and C3d and properdin staining was associated with the proportion of 
cellular crescents, confirming the role of C3d-staining as an independent risk factor for the 
development of ESRD (42) 
Expression of the two C5a receptors, C5aR and C5L2, was mainly found on infiltrating 
neutrophils and macrophages. C5L2 was upregulated, whereas expression of C5aR was 
downregulated and correlated with serum creatinine levels at diagnosis and the extent of 
interstitial fibrosis. (39-41) 
All these findings in plasma, urine and kidneys of AAV patients provide additional evidence 
that activation of the alternative complement pathway occurs in the development of AAV 
and may have a role in clinical stratification of disease severity. 
Complement-targeted therapies in AVV 
Current therapeutic options for AAV are based on general immune-suppression 
administrated as induction treatment with cyclophosphamide or rituximab and steroids. For 
maintenance treatment, azathioprine, methotrexate and rituximab are recommended. This 
standard of care has transformed these group of entities from a usually fatal disease into a 
chronic condition with co-morbidity and high relapse risk. (43) 
In this setting, finding new therapies to save steroid doses and prevent recurrence of 
disease are one of the main priorities. Given the background that complement is actively 
involved in pathogenesis, complement targeting therapies are very attractive option to 
solve this important clinical issue.(44) 
In recent years, drugs have been designed to target specifically one of the activation 
pathways of the complement cascade; it is possible to avoid blocking complement 
activation itself, by blocking the detection of activated complement fragments by cellular 
complement receptors instead. Using specific inhibitors that block one particular aspect of 
complement activation, the therapeutic result can be reached without affecting the other 
critical aspects of complement activation and innate immune response. (44) 
There are several classes of complement-inhibiting molecules in different phases of 
development, including therapeutic blocking antibodies, purified human proteins, 
recombinant proteins from pathogens, peptides or small interfering RNAs. (25,44) 
Only two types of these drugs are clinically available: the C5-blocking antibody eculizumab 
(Soliris®, Alexion Pharmaceuticals, Boston, Massachusetts, USA) and several C1-inhibitor 
(C1-INH) preparations (Cinryze®, Shire Pharmaceuticals, Dublin, Ireland; Berinert®, CSL 
Behring, King of Prussia, Pennsylvania, USA and Ruconest®, Pharming Group, Leiden, 
The Netherlands). The C1-INH preparations are mostly used for the treatment of angio-
oedema.(45) 
Eculizumab has been available for clinical use for more that 10 years in the treatment of 
paroxysmal nocturnal haematuria (PNH) and atypical haemolytic uremic syndrome 
(aHUS), with very good outcomes and important information about its use and safety is 
available elsewhere. (46-48) 
Due to differences between PNH and AAV pathogenesis, efforts for complement inhibition 
in AAV has been focused on inhibiting the signaling of the C5aR. Complement target 
therapy in AAV has been tested in animal models, blocking C5 activation prior to lesion 
induction could prevent MPO-ANCA-triggered vasculitis in mice and most of the effect of 
complement activation was mediated by C5aR1, the receptor for C5a (49-50).  
These observations clearly indicate C5 and C5aR as possible therapeutic targets in 
experimental AAV using a small compound inhibitor of the C5a receptor with dose-
dependent inhibition effect of MPO-ANCA induced GN. (51) 
In line with these observations, there was no major role for the membrane attack complex 
(C5b-9) in the pathogenesis of AAV. Eculizumab avoids the cleavage of C5 but at the 
same time completely blocks membrane attack complex (MAC) formation in pathogens, 
potentially adding an undesirable and unnecessary risk of severe infections in the setting 
of AAV. (52) 
 CCX168: The oral C5aR blocker experience in ANCA associated vasculitis 
As a consequence of these bench findings, clinical trials have been launched to test the 
safety and efficacy of an orally available human C5aR blocker, the small molecule 
CCX168 (Avacopan®, ChemoCentryx, Mountain View, California, USA). The phase I 
studies revealed a good safety profile, while producing more than 90% receptor blockade 
in inflammatory cells in the blood throughout the day.(53) 
Next, the C5aR inhibitor on Leukocytes Exploratory ANCA-associated Renal Vasculitis 
(CLEAR) trial was performed using CCX168. In this randomised, double-blind, placebo-
controlled phase II trial, CCX168 was orally administered to AAV patients.(54) Three 
groups were compared: one receiving the standard treatment (cyclophosphamide/
rituximab and high-dose prednisolone and placebo), one receiving CCX168 and 
prednisolone (cyclophosphamide/rituximab and low-dose prednisolone and 30mg CCX168 
twice daily) and the third group receiving CCX168 without prednisolone 
(cyclophosphamide/rituximab and no prednisolone and 30mg CCX168 twice daily). At 12 
weeks, it was observed that CCX168 was well tolerated with no unexpected adverse 
events. It was concluded that CCX168 was at least equally effective as the standard of 
care.(54) Following this trial, the Clinical ANCA Vasculitis Safety and Efficacy Study of 
Inhibitor of C5aR (CLASSIC) was performed. In this dose-ranging Phase II study of 
CCX168 which was added to standard of care, no safety concerns were reported and a 
dose-response effect of the treatment was established. (55) Currently, a Phase III Clinical 
Trial of CCX168 in AAV (ADVOCATE) is ongoing and will assess the proportion of patients 
achieving remission at 26 and 52 weeks. (56) 
Conclusions 
Despite the use of the best available current therapies and achieving high levels of early 
clinical responses, ESRD caused by ANCA associated GN is an avoidable outcome yet, 
with rates approaching 40%. Major hurdles to management include the complex balance 
between toxicity associated with steroids and other immunosuppressive therapies and the 
risk of recurrence. The recent advances in the understanding of the role of complement in 
AAV pathogenesis clearly indicate C5 and C5aR as possible therapeutic targets in 
experimental AAV and open the way for clinical use of complement target therapy in the 
near future. 
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